Saturday 17 October 2026 Export KOD’s income statement to Excel — free account

Kodiak Sciences Inc.

In the quarter to June 2026, EPS fell 1.94% and free cash flow fell 33.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

85.75 2.37 −2.69%

Follow KOD

Alert me

Market cap: $5.5B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 216.99

Total sells 2.22

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	3	—
Sell	—	—	—	—	—	1	—	1	—	—	—	—

Insider Ownership 8.22%

Capital & Financial Ratios $m

Market Cap 5,540.00

Revenue —

Net Income (241.99)

Free Cash Flow (159.90)

Net Debt (125.90)

Current Ratio 2.49

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 87.90

Past 5Y EPS Growth —

This Y EPS Growth 5.58%

Next Y EPS Growth 5.61%

Next Y revenue growth —

Next 5Y EPS Growth 50.98%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 99.34%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	286	168	210	126
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	289	172	215	131

	2023	2024	2025	Q'26
Payables	14	4	13	13
ST’ Debt	—	—	—	—
Other	—	—	—	—
	42	26	46	53

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(28.81%)	(28.81%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(40)	(46)	—	—	—
’25	(29)	(35)	(33)	(39)	(136)
’24	(40)	(26)	(21)	(30)	(117)
’23	(47)	(42)	(33)	(32)	(154)
’22	(43)	(55)	(53)	(55)	(206)
’21	(35)	(37)	(52)	(59)	(182)
’20	(18)	(14)	(25)	(27)	(83)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(41)	(47)	—	—	—
’25	(29)	(35)	(33)	(39)	(137)
’24	(40)	(27)	(21)	(30)	(118)
’23	(59)	(43)	(33)	(60)	(196)
’22	(61)	(71)	(60)	(61)	(254)
’21	(41)	(51)	(84)	(70)	(246)
’20	(18)	(14)	(26)	(32)	(90)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.94)	(1.05)	—	—	—
’25	(1.09)	(1.03)	(1.16)	(1.04)	(4.32)
’24	(0.82)	(0.86)	(0.84)	(0.84)	(3.35)
’23	(1.35)	(1.53)	(0.95)	(1.13)	(4.97)
’22	(1.83)	(1.74)	(1.47)	(1.35)	(6.39)
’21	(0.98)	(1.08)	(1.30)	(1.79)	(5.16)
’20	(0.54)	(0.58)	(0.80)	(0.97)	(2.91)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	5.65	5.86	35.49	73.19	4.90	1.37	2.19	1.92	Analyst estimates 2026–2028 Powerpack
	High	—	—	11.10	81.00	159.18	171.21	90.24	9.80	11.60	31.18
People
People	Employees	—	28	28	31	72	93	112	111	109	124
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(17)	(28)	(41)	(47)	(133)	(267)	(334)	(260)	(176)	(230)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(17)	(28)	(41)	(47)	(133)	(267)	(334)	(260)	(176)	(230)
	Depreciation	0	1	0	1	4	9	10	25	27	26
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(2.38)	(3.72)	(2.77)	(1.25)	(2.91)	(5.16)	(6.39)	(4.97)	(3.35)	(4.32)
	Cash flow	(2.23)	(2.35)	(1.94)	(1.03)	(1.82)	(3.52)	(3.95)	(2.94)	(2.23)	(2.56)
	Capex	(0.11)	(0.03)	(0.04)	(0.01)	(0.15)	(1.22)	(0.91)	(0.79)	(0.01)	(0.01)
	Free cash flow	(2.33)	(2.38)	(1.98)	(1.05)	(1.98)	(4.74)	(4.86)	(3.73)	(2.24)	(2.57)
	Book value	(5.70)	(9.15)	5.80	9.12	18.82	12.81	8.35	5.07	2.86	2.96
	Shares, m	7	8	15	38	46	52	52	52	53	53
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(16)	(18)	(29)	(39)	(83)	(182)	(206)	(154)	(117)	(136)
	Capex	(1)	0	(1)	0	(7)	(63)	(47)	(41)	0	(1)
	Free cash flow	(17)	(18)	(30)	(40)	(90)	(246)	(254)	(196)	(118)	(137)
Balance, $m
Balance, $m	Working capital	8	(8)	86	328	941	670	434	248	146	169
	Total debt	0	10	—	2	75	176	178	—	—	—
	Net debt	(10)	9	(88)	(336)	(969)	(732)	(479)	(286)	(168)	(210)
	Shareholders’ equity	(41)	(69)	87	345	861	663	436	266	150	157
Returns, %
Returns, %	ROA	(226.70)	(363.80)	(86.85)	(21.00)	(18.66)	(27.08)	(42.50)	(45.46)	(43.24)	(66.94)
	ROIC	0.00	0.00	0.00	(346.29)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	31.13	50.88	(458.06)	(21.92)	(22.07)	(35.04)	(60.72)	(74.22)	(84.70)	(149.49)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RYTM Rhythm Pharmaceuticals, Inc.	$6.1B	— (loss-making)	— (loss-making)	+46.91% (above 0%: growing)	n/m	+60.74% (above 0%: growing)	87.47%	(68.14%)	Compare
LGND Ligand Pharmaceuticals Incorporated	$6.0B	29.5×	54.7×	+33.73% (above 0%: growing)	+868.00% (above 0%: growing)	+35.53% (above 0%: growing)	94.95%	13.49%	Compare
IMVT Immunovant, Inc.	$5.7B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
KOD Kodiak Sciences Inc.	$5.5B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
Median of peers	$5.4B	—	—	+42.42%	—	−5.31%	41.39%	0.00%

All 614 Biotechnology stocks →

Kodiak Sciences Inc. (KOD) key facts

Concern: Kodiak Sciences Inc. reported a net loss of $230.0 million, or a loss of $4.32 per share, for fiscal 2025.
Kodiak Sciences Inc. (KOD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KOD traded at $85.75, a market capitalization of $5.5 billion.
Return on equity was −149.5% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.